A Study of Bevacizumab Therapy in Patients With Newly Diagnosed High-Grade Gliomas and Diffuse Intrinsic Pontine Gliomas

Exclusion Criteria

• •Patients with metastatic disease (i.e. M+ disease, or disease anywhere other than primary site).
• •Patients with evidence of a new intracranial hemorrhage that is larger than a punctate size on baseline MRI scan.
• •Allergies: Patients with a history of allergic reaction to Chinese hamster ovary cell products, or other recombinant human antibodies.
• •Pregnant or breast feeding women will not be entered on this study.
• •Patients of childbearing or child-fathering potential must be willing to use a medically acceptable form of birth control, which includes abstinence, while being treated on this study.
• •Infection: Patients who require IV antibiotics at time of enrollment, or who are currently receiving treatment for Clostridium difficile infection are excluded.
• •Thrombosis: Patients must not have been previously diagnosed with a deep venous or arterial thrombosis (including pulmonary embolism), and must not have a known thrombophilic condition.
• •Serious or Non-Healing Wounds
• •Surgical Procedures: Patients who have had major surgery should not receive the first dose of bevacizumab until 28 days after major surgery.
• •Patients with uncontrolled systemic hypertension.
• •Proteinuria with a urine protein (albumin)/creatinine ratio of ≥1.0.